Extracellular vesicles and cancer stem cells: a deadly duo in tumor progression

• Main Authors: Akram Tayanloo-Beik (Author), Azin Eslami (Author), Masoumeh Sarvari (Author), Hasan Jalaeikhoo (Author), Mohsen Rajaeinejad (Author), Mohsen Nikandish (Author), Ali Faridfar (Author), Mostafa Rezaei-Tavirani (Author), Ahmad Rezazadeh Mafi (Author), Bagher Larijani (Author), Babak Arjmand (Author)
• Format: Book
• Published: Frontiers Media S.A., 2024-07-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.
• Notes: 1970-5557; 10.3389/or.2024.1411736
• Keywords: cancer stem cells; extracellular vesicles; tumor microenvironment; drug resistance; precision medicine; Other systems of medicine; RZ201-999; Internal medicine; RC31-1245
• Source: Oncology Reviews, Vol 18 (2024)

The global incidence of cancer is increasing, with estimates suggesting that there will be 26 million new cases and 17 million deaths per year by 2030. Cancer stem cells (CSCs) and extracellular vesicles (EVs) are key to the resistance and advancement of cancer. They play a crucial role in tumor dynamics and resistance to therapy. CSCs, initially discovered in acute myeloid leukemia, are well-known for their involvement in tumor initiation, progression, and relapse, mostly because of their distinct characteristics, such as resistance to drugs and the ability to self-renew. EVs, which include exosomes, microvesicles, and apoptotic bodies, play a vital role in facilitating communication between cells within the tumor microenvironment (TME). They have a significant impact on cellular behaviors and contribute to genetic and epigenetic changes. This paper analyzes the mutually beneficial association between CSCs and EVs, emphasizing their role in promoting tumor spread and developing resistance mechanisms. This review aims to investigate the interaction between these entities in order to discover new approaches for attacking the complex machinery of cancer cells. It highlights the significance of CSCs and EVs as crucial targets in the advancement of novel cancer treatments, which helps stimulate additional research, promote progress in ideas for cancer treatment, and provide renewed optimism in the effort to reduce the burden of cancer.